Acta Scientific Cancer Biology (ASCB) (ISSN: 2582-4473)

Review Article Volume 5 Issue 6

Does the Type of Surgery After Preoperative Systemic Therapy for T3/T4 Breast Cancer Impact Survival?

Jamila Alazhri1,4*, Tulay Koru-Sengul2,3, Feng Miao3, Margaret M Byrne2,5 and Eli Avisar1,3

1Division of Surgical Oncology, Department of Surgery, University of Miami Miller School of Medicine, Miami, FL, USA
2Department of Public Health Sciences, University of Miami Miller School of Medicine, Miami, FL, USA
3Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA
4Division of Breast and Endocrine Surgery, Department of Surgery, King Fahad Specialist Hospital, Dammam, Saudi Arabia
5H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA

*Corresponding Author: Jamila Alazhri, Breast and Endocrine Surgery Division, Department of Surgery, King Fahad Specialist Hospital, Dammam, Saudi Arabia.

Received: April 01, 2021; Published: May 21, 2021


Introduction: Our purpose was to study the impact of the extent of surgery on survival of women with T3/T4 breast cancer treated with preoperative systemic therapy (PST) in form of chemotherapy, hormonal therapy, or both.

Methods: Population-based Florida Cancer Data Registry was screened for women diagnosed with T3/T4 breast cancer who received PST followed by either breast conserving surgery (BCS) or mastectomy. A multivariable Cox regression model was used to identify significant predictors of overall survival. Adjusted hazard ratio (aHR) and 95% confidence interval (95%CI) were calculated.

Results: Out of 712 patients receiving PST, 72 (10%) had BCS and 640 (90%) had mastectomy. After covariable adjustment, patients who received both chemo and hormonal PST had better prognosis than patients with chemotherapy alone (aHR=1.90, 95%CI: 1.20 - 3.01, p = 0.006) or hormonal therapy alone (1.95, 0.84 - 4.56, p = 0.122). Hispanic origin (0.50, 0.27 - 0.92, p = 0.027) positively impacted survival. Medicare (1.70, 1.08 - 2.68, p = 0.021) and uninsured (1.69, 1.10 - 2.60, p = 0.016) compared to private insurance, poorly-differentiated/undifferentiated (2.24, 1.04 - 4.82, p = 0.039) compared to well-differentiated grade, and distant SEER stage (4.13, 1.68 - 10.12, p = 0.002) compared to localized were significant predictors of worse survival. There was no significant difference in survival between women who had mastectomy compared to BCS (1.35, 0.82 - 2.21, p = 0.234). In the subgroup of patients who had mastectomy, radiotherapy resulted in significantly better survival than no radiotherapy (HR 0.68, 0.47-0.99, p = 0.044).

Conclusion: The type of surgery after PST for T3/T4 breast cancer does not impact overall survival. BCS could be considered for patients with T3/T4 tumors after PST.

Keywords: Locally Advanced Breast Cancer; T3 Breast Cancer; T4 Breast Cancer; Preoperative Systemic Therapy; Neoadjuvant Chemotherapy; Breast Conserving Surgery; Mastectomy; Florida


  1. J Al-Azhri., et al. “Predictors of surgery types after neoadjuvant therapy for advanced stage breast cancer: Analysis from Florida population-based cancer registry (1996-2009)”. Breast Cancer (Auckl) 9 (2015): 99-108.
  2. Hwang ES., et al. “Survival after lumpectomy and mastectomy for early stage invasive breast cancer”. Cancer 7 (2013): 1402-1411.
  3. Cho JH., et al. “Oncologic safety of breast-conserving surgery compared to mastectomy in patients receiving neoadjuvant chemotherapy for locally advanced breast cancer”. Journal of Surgical Oncology8 (2013): 531-536.
  4. Litiere S., et al. “Breast conserving therapy versus mastectomy for stage I-II breast cancer: 20 year follow-up of the EORTC 10801 phase 3 randomised trial”. Lancet Oncology4 (2012): 412-419.
  5. Fisher B., et al. “Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18”. Journal of Clinical Oncology7 (1997): 2483-2493.
  6. Cance WG., et al. “Long-term outcome of neoadjuvant therapy for locally advanced breast carcinoma - Effective clinical downstaging allows breast preservation and predicts outstanding local control and survival”. Annals of Surgery3 (2002): 295-303.
  7. Touboul E., et al. “Possibility of conservative local treatment after combined chemotherapy and preoperative irradiation for locally advanced noninflammatory breast cancer”. International Journal of Radiation Oncology 5 (1996): 1019-1028.
  8. Fitzal F., et al. “Oncologic safety of breast conserving surgery after tumour downsizing by neoadjuvant therapy: a retrospective single centre cohort study”. Breast Cancer Research and Treatment 1 (2011): 121-128.
  9. Martinez ME., et al. “Breast cancer among Hispanic and non-Hispanic White women in Arizona”. Journal of Health Care for the Poor and Underserved 4 (2007): 130-145.
  10. Banegas MP and Li CI. “Breast cancer characteristics and outcomes among Hispanic Black and Hispanic White women”. Breast Cancer Research and Treatment3 (2012): 1297-1304.
  11. Frost F., et al. “Breast cancer survival among new Mexico Hispanic, American Indian, and non-Hispanic white women (1973-1992)”. Cancer Epidemiology, Biomarkers and Prevention 11 (1996): 861-866.
  12. Shavers VL., et al. “Racial/ethnic variation in clinical presentation, treatment and survival among breast cancer patients under age 35”. Cancer Epidemiology, Biomarkers and Prevention 10 (2002): 1203s-1203s.
  13. Smigal C., et al. “Trends in breast cancer by race and ethnicity: Update 2006”. CA: A Cancer Journal for Clinicians 3 (2006): 168-183.
  14. Franzini L., et al. “Understanding the Hispanic paradox”. Ethnicity and Disease. Autumn3 (2006): 496-518.
  15. Krzyzak M., et al. “Breast Cancer Survival Gap between Urban and Rural Female Population in Podlaskie Voivodship, Poland, in 2001-2002. Population Study”. Annals of Agricultural and Environmental Medicine 2 (2010): 277-282.
  16. Mitchell KJ., et al. “Rural-urban differences in the presentation, management and survival of breast cancer in Western Australia”. Breast 6 (2006): 769-776.
  17. Howe HL., et al. “Urban-Rural Differences in the Management of Breast-Cancer”. Cancer Cause Control2 (1993): 172-172.
  18. Shi RH., et al. “Effects of payer status on breast cancer survival: a retrospective study”. BMC Cancer 15 (2015).
  19. Shi RH., et al. “Disparities in breast cancer relative survival according to payer status: Findings from national cancer data bank”. Cancer Research19 (2014): 4128.
  20. Huang EH., et al. “Postmastectomy radiation improves local-regional control and survival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy”. Journal of Clinical Oncology23 (2004): 4691-4699.
  21. Mak KS and Harris JR. “Radiotherapy Issues After Neoadjuvant Chemotherapy”. Journal of the National Cancer Institute. Monographs51 (2015): 87-89.
  22. Collab EBCT. “Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trials”. Lancet9804 (2011): 1707-1716.
  23. Smith BD. “Using Chemotherapy Response to Personalize Choices Regarding Locoregional Therapy: A New Era in Breast Cancer Treatment?”. Journal of Clinical Oncology32 (2012): 3913-3915.
  24. Mamounas EP., et al. “NRG Oncology/NSABP B-51/RTOG 1304: Phase III trial to determine if chest wall and regional nodal radiotherapy (CWRNRT) post mastectomy or the addition of RNRT to whole breast RT post breast-conserving surgery reduces invasive breast cancer recurrence-free interval (IBCR-FI) in patients with pathologically positive axillary nodes who are ypN0 after neoadjuvant chemotherapy”. Journal of Clinical Oncology 37 (2019): 15.
  25. Pierga JY., et al. “Prognostic factors for survival after neoadjuvant chemotherapy in operable breast cancer: the role of clinical response”. European Journal of Cancer8 (2003): 1089-1096.


Citation: Jamila Alazhri., et al. “Does the Type of Surgery After Preoperative Systemic Therapy for T3/T4 Breast Cancer Impact Survival?”. Acta Scientific Cancer Biology 5.6 (2021): 26-36.


Copyright: © 2021 Jamila Alazhri., et al.. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Acceptance rate35%
Acceptance to publication20-30 days

Indexed In

News and Events

  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is June 25, 2021.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of “Best Article of the Issue”.
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.
  • Contact US